Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

Beam Therapeutics in the NEWS

Beam Therapeutics (BEAM) announced that Eli Lilly (LLY) has agreed to acquire certain rights under . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.